Evidence map›Paper›PMID 31099910›Full record

Trial reportJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2019

Gender-Affirming Hormone Treatment Decreases Bone Turnover in Transwomen and Older Transmen.

Mariska C Vlot, Chantal M Wiepjes, Renate T de Jongh, Guy T'Sjoen, Annemieke C Heijboer, Martin den Heijer

Open access · hybridAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 4 pooled it
5.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 4 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Gender-affirming hormonal therapy for transgender and gender-diverse people-A narrative review.Best practice & research. Clinical obstetrics & gynaecology · 2023
    Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Observational
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Mariska C VlotDepartment of Internal Medicine and Center of Expertise on Gender Dysphoria, Amsterdam UMC, Vrije Universiteit Amsterdam, A, msterdam, The Netherlands.
Chantal M WiepjesDepartment of Internal Medicine and Center of Expertise on Gender Dysphoria, Amsterdam UMC, Vrije Universiteit Amsterdam, A, msterdam, The Netherlands.
Renate T de JonghDepartment of Internal Medicine and Center of Expertise on Gender Dysphoria, Amsterdam UMC, Vrije Universiteit Amsterdam, A, msterdam, The Netherlands.
Guy T'SjoenDepartment of Endocrinology, Center for Sexology and Gender, Ghent University Hospital, Ghent, Belgium.
Annemieke C HeijboerDepartment of Clinical Chemistry, Endocrine laboratory, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Martin den HeijerDepartment of Internal Medicine and Center of Expertise on Gender Dysphoria, Amsterdam UMC, Vrije Universiteit Amsterdam, A, msterdam, The Netherlands.
Vrije Universiteit Amsterdam · NLAmsterdam University Medical Centers · NLGhent University Hospital · BE

Funding

Abbott Laboratories
6 · The paper itself

Abstract

Sex steroids play a key role in bone turnover and preserving BMD; hence, gender-affirming hormone treatment (HT) in transgender people affects bone metabolism. Most studies have looked into the effect of HT on changes in BMD; however, they do not provide insights into changes in bone metabolism caused by HT. This study investigated changes in bone turnover markers (BTMs) and sclerostin, as well as their correlations with change in BMD in transwomen and transmen during the first year of HT. Transwomen received estradiol and antiandrogens; transmen received testosterone. Sclerostin; P1NP; alkaline phosphatase (ALP); CTx; and BMD of the total hip, the femoral neck, and the lumbar spine were evaluated at baseline and after 1 year of HT. There were 121 transwomen (median age 30 years, interquartile range [IQR] 24 to 41 years) and 132 transmen (median age 24 years, IQR 21 to 33 years) included in the study. In transwomen, ALP decreased in 19% (95% CI, -21 to-16), CTx in 11% (95% CI, -18 to-4), and sclerostin in 8% (95%CI, -13 to-4) of study participants after 1 year of HT. In contrast, in transmen P1NP, ALP, and sclerostin increased in 33% (95% CI, 24 to 42), 16% (95% CI, 12 to 20), and 15% (95% CI, 10 to 20) of study participants, respectively, after 1 year of HT. No age differences were seen in transwomen, whereas in transmen aged ≥50 years a decrease in all BTMs was found in contrast with the other age groups. These transmen had low estrogen concentration at the start of HT based on their postmenopausal state before the start of HT; their estradiol concentrations increased during testosterone treatment. Changes in BTMs and BMD were weakly correlated (correlation coefficient all <0.30). To conclude, 1 year of HT resulted in decreased bone turnover in transwomen and older transmen, whereas it increased in younger transmen. The decrease in bone resorption in older transmen shows the importance of estrogen as a key regulator of bone turnover. © 2019 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals, Inc.

Indexed as

Androgen AntagonistsEstradiolTestosteroneTransgender PersonsAdultBiomarkersBone DensityBone RemodelingFemaleGender-Affirming ProceduresHumansMaleAndrogen AntagonistsBiomarkersEstradiolTestosteroneBONE TURNOVER MARKERGENDER-AFFIRMING HORMONE TREATMENTP1NPSCLEROSTINTRANSGENDER

Identifiers

PMID31099910
PMCPMC6852079
OpenAlexW2945257103

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.